Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Methyldopa

Methyldopa

Methyldopa is a medication primarily used to treat high blood pressure.
It works by reducing the activity of the sympathetic nervous system, which helps lower blood pressure.
Methyldopa is often prescribed for pregnant women with hypertension, as it is considered relatively safe for the developing fetus.
Researchers can use PubCompare.ai's AI-driven platform to easily locate relevant research protocols on Methyldopa from literature, preprints, and patents, while conducting smart comparisons to identify the most reproducible and accurate methods.
This can help enhance Methyldopa research and acheive better results.

Most cited protocols related to «Methyldopa»

1
Early Parkinson's Disease Cohort Study
PD and HC subjects of similar age and gender from 24 study sites in the US (18), Europe (5) and Australia (1) were enrolled after obtaining informed consent. We acknowledge that the early PD cohort likely includes a small number of subjects with other DAT deficit parkinsonian syndromes such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and cortical basal syndrome (CBS), which may be indistinguishable from PD at the earliest stages of disease. At each study visit, the investigators reassess the subject diagnosis to identify any non‐PD subjects.
This study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice (GCP) guidelines after approval of the local ethics committees of the participating sites. At enrollment, PD subjects were required to be age 30 years or older, untreated with PD medications (levodopa, dopamine agonists, MAO‐B inhibitors, or amantadine), within 2 years of diagnosis, Hoehn and Yahr <3, and to have either at least two of resting tremor, bradykinesia, or rigidity (must have either resting tremor or bradykinesia) or a single asymmetric resting tremor or asymmetric bradykinesia. All PD subjects underwent dopamine transporter (DAT) imaging with 123I Ioflupane or vesicular monoamine transporter (VMAT‐2) imaging with 18F AV133 (Australia only) and were only eligible if DAT or VMAT‐2 imaging demonstrated dopaminergic deficit consistent with PD in addition to clinical features of the disease. Study investigators evaluated enrolled PD subjects to assess absence of current or imminent (6 months) disability requiring PD medications, though subjects could initiate PD medications at any time after enrollment if the subject or investigator deemed it clinically necessary. Those subjects screened as potential PD subjects who were ineligible due to DAT or VMAT‐2 scans without evidence of dopaminergic deficit (SWEDD) were eligible to be enrolled in a SWEDD cohort.4 HC subjects were required to be age 30 years or older without an active, clinically significant neurological disorder or a first‐degree relative with PD. All enrolled subjects agreed to complete all study evaluations, including lumbar puncture.
PD and SWEDD subjects were excluded if they had a clinical diagnosis of dementia or had taken PD medications within 60 days of baseline or for longer than 60 days in total. HC subjects were excluded if they had a Montreal Cognitive Assessment (MoCA) total score ≤26. All subjects were excluded if they were treated with neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or amphetamine derivative within 6 months or were currently treated with anticoagulants that might preclude safe completion of the lumbar puncture.
Marek K., Chowdhury S., Siderowf A., Lasch S., Coffey C.S., Caspell‐Garcia C., Simuni T., Jennings D., Tanner C.M., Trojanowski J.Q., Shaw L.M., Seibyl J., Schuff N., Singleton A., Kieburtz K., Toga A.W., Mollenhauer B., Galasko D., Chahine L.M., Weintraub D., Foroud T., Tosun‐Turgut D., Poston K., Arnedo V., Frasier M, & Sherer T. (2018). The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort. Annals of Clinical and Translational Neurology, 5(12), 1460-1477.
Publication 2018
123I-ioflupane Amantadine Amphetamine Anticoagulants Antipsychotic Agents Bradykinesia Cortex, Cerebral Dementia Diagnosis Disabled Persons Dopamine Agonists Gender Hydrochloride, Dopamine Levodopa Methyldopa Methylphenidate Metoclopramide Monoamine Oxidase Inhibitors Multiple System Atrophy Muscle Rigidity Nervous System Disorder Parkinsonian Disorders Pharmaceutical Preparations Progressive Supranuclear Palsy Punctures, Lumbar Radionuclide Imaging Regional Ethics Committees Reserpine Resting Tremor SLC6A3 protein, human Syndrome Vesicular Monoamine Transport Proteins Volumetric-Modulated Arc Therapy
2
CRISPR-Cas9 System Development for Myceliophthora thermophila
All primer sequences used in this study are listed in Additional file 7: Table S1. All PCR products were amplified using Phusion high-fidelity DNA polymerase (Thermo Fisher, Waltham, MA, USA). A codon-optimized Cas9 gene with attached hac-1 (MYCTH_2310995) nuclear localization signals (NLS-Cas9-NLS) was synthesized by Life Technologies (Invitrogen) for expression in M. thermophila and M. heterothallica. The synthetic NLS-Cas9-NLS, the strong constitutive tef1 (MYCTH_2298136) promoter of M. thermophila, and the TtprC terminator were amplified using paired primers (Additional file 7: Table S1). With the aid of a NEB Gibson assembly kit, these amplification products were assembled to form a Ptef1-Cas9-TtprC cassette (Additional file 8) and inserted into a p0380-bar plasmid [56 (link)] carrying the bar marker to generate the Cas9-expression vector p0380-bar-Ptef1-Cas9-TtprC. A Gibson assembly kit was also used to construct a Cas9-eGFP-expression vector (p0380-bar-Ptef1-Cas9-eGFP-TtprC) in which enhanced GFP (eGFP) was fused to Cas9 as a reporter gene (Additional file 8). To generate sgRNA expression plasmids, an sgRNA scaffold was synthesized by Life Technologies. To express sgRNA in protoplasts, the M. thermophila U6 promoter was amplified from ATCC 42464 genomic DNA using the primer pair U6-F/R (Additional file 7: Table S1) and then fused to the sgRNA scaffold fragment by fusion PCR using U6-F and gRNA-R (Additional file 7: Table S1). The resulting fusion fragment was cloned into a pJET1.2/blunt cloning vector to create the corresponding plasmid U6p-sgRNA (Additional file 9).
To select for specific sgRNAs targeting amdS (GenBank number: M16371.1), cre-1 (MYCTH_2310085), res-1 (MYCTH_2302052), gh1-1 (MYCTH_115968), and alp-1 (MYCTH_2303011), all sgRNA target sites in the genome of M. thermophila were identified using the sgRNACas9 tool [57 (link)]. sgRNA target sites with high scores were chosen and the corresponding oligos were ordered (Additional file 7: Table S1). All protospacer sequences used to target the five different genes are presented in Table 1. A target-directed M. thermophila U6 promoter-driven sgRNA was created by overlapping PCR with the primers given in Additional file 7: Table S1 and cloned into a pJET1.2/blunt cloning vector, which yielded the corresponding plasmids U6p-amdS-sgRNA, U6p-cre1-sgRNA, U6p-res1-sgRNA, U6p-gh1-1-sgRNA, and U6p-alp1-sgRNA (Additional file 9).
Liu Q., Gao R., Li J., Lin L., Zhao J., Sun W, & Tian C. (2017). Development of a genome-editing CRISPR/Cas9 system in thermophilic fungal Myceliophthora species and its application to hyper-cellulase production strain engineering. Biotechnology for Biofuels, 10, 1.
Full text: Click here
Publication 2017
2',5'-oligoadenylate Cloning Vectors Codon DNA-Directed DNA Polymerase Genes Genes, Reporter Genes, vif Genome Methyldopa Oligonucleotide Primers Plasmids Protoplasts
3
CRISPR-Cas9 for Fungal Genome Editing
Transformation of M. thermophila and M. heterothallica protoplasts was performed according to a previously described procedure [44 (link)]. For amdS mutagenesis, the promoter Ptef1 (MYCTH_2298136) and the full-length acetamidase-encoding gene amdS (GenBank number: M16371.1) were amplified from genomic DNA of M. thermophila and the plasmid p3SR2 using the paired primers Ptef1-F2/R2 and amdS-F/R, respectively. The amdS gene was fused with Ptef1 by overlapping PCR using the primer pair Ptef1-F2/amdS-R. The Ptef1-amdS cassette was then ligated into the EcoRI and HindIII sites of a pCAMBIA-0380 plasmid [56 (link)], thereby generating the expression plasmid p0380-Ptef1-amdS. This constructed plasmid was transformed into the WT strain via Agrobacterium-mediated transformation. Colonies grown for 5 days at 35 °C were selected in medium containing 10 mM acetamide as the sole nitrogen source. Positive transformants were identified by PCR with paired primers (Additional file 7: Table S1). From these transformants, the amdS expression strain M1 was chosen and used for further CRISPR/Cas9 manipulation. Briefly, 10 µg of the Cas9-expression PCR cassette bar-Ptef1-Cas9-TtprC and the gRNA expression PCR product U6p-amdS-sgRNA at a molar concentration ratio of 1:1 was co-transformed into protoplasts of the recipient strain M1. After transformation, amdS mutants were inoculated onto MM agar plates supplemented with 2 mg mL−1 FAA and 100 µg mL−1 phosphinothricin. After 3 days incubation at 35 °C, FAA-resistant mutants were isolated and tested for growth on acetamide medium, followed by identification and sequencing via PCR with paired primers (Additional file 7: Table S1).
For single-gene editing, 10 µg of the Cas9-expression PCR cassette bar-Ptef1-Cas9-TtprC, gRNA expression PCR cassette U6p-cre1-sgRNA, and donor-cre1 was mixed at a molar concentration ratio of 1:1:1 and added to the fungal protoplasts. Control experiments were performed by adding 10 µg of donor-cre1 alone, or only the Cas9 cassette and donor-cre1, or only U6p-cre1-sgRNA and donor-cre1 to the fungal protoplasts. Transformants were screened for bar resistance with phosphinothricin (100 µg mL−1) and neo resistance with G418 (40 µg mL−1), followed by PCR identification with paired primers (Additional file 7: Table S1).
For multiple genomic edits, the generated amdS mutant M2 containing a Cas9 expression chassis was used as a host. Multiple genomic modification involving the cre-1, res-1, gh1-1, and alp-1 loci was performed in M2 protoplasts through co-transformation of two, three, or four sets of sgRNA expression cassettes and donor DNA fragments at the same molar concentration. The putative transformants were selected on MM supplemented with 100 µg mL−1 phosphinothricin and 40 µg mL−1 G418, followed by sequential identification via PCR with paired primers (Additional file 7: Table S1).
Liu Q., Gao R., Li J., Lin L., Zhao J., Sun W, & Tian C. (2017). Development of a genome-editing CRISPR/Cas9 system in thermophilic fungal Myceliophthora species and its application to hyper-cellulase production strain engineering. Biotechnology for Biofuels, 10, 1.
Full text: Click here
Publication 2017
acetamidase acetamide actinomycin D1 Agar Agrobacterium antibiotic G 418 Clustered Regularly Interspaced Short Palindromic Repeats Deoxyribonuclease EcoRI Genes Genome Methyldopa Molar Mutagenesis Nitrogen-10 Oligonucleotide Primers phosphinothricin Plasmids Protoplasts Strains Tissue Donors
4
Comprehensive Protocols for Genetic Manipulation of Aspergillus niger

A. niger strains used in this study are listed in Table 1. Strains were cultivated in minimal medium (MM; (Bennett and Lasure 1991 )) containing 55 mM glucose, 7 mM KCl, 11 mM KH2PO4, 70 mM NaNO3, 2 mM MgSO4, 76 nM ZnSO4, 178 nM H3BO3, 25 nM MnCl2, 18 nM FeSO4, 7.1 nM CoCl2, 6.4 nM CuSO4, 6.2 nM Na2MoO4, 174 nM EDTA; or in complete medium containing, in addition to MM, 0.1% (w/v) casamino acids and 0.5% (w/v) yeast extract. When required, 10 mM uridine and/or 100 µg/ml of hygromycin was added. When using the amdS as selection marker, strains were grown in MM without NaNO3 and supplemented with 10 mM acetamide and 15 mM cesium chloride.

Aspergillus niger strains used in this study

NameGenotypeReference
N402cspA1, amdS−Bos et al. (1988 (link))
AB4.1pyrG−, amdS−van Hartingsveldt et al. (1987 (link))
MA70.15aΔkusA, pyrG−, amdS+Meyer et al. (2007 (link))
MA78.6aΔkusA, amdS+This study
NC4.1aΔkusA, pyrG−, amdS−This study
NC5.1aΔkusA, pyrG+, amdS−This study
NC6.2ΔkusA, pyrG+, amdS+, ΔhacAThis study
NC7.1ΔkusA, pyrG+, amdS+, ΔireA/ireAThis study
NC8.1ΔkusA, pyrG+, amdS+, ΔhacA, pAMA-hacAThis study
NC9.1ΔkusA, pyrG+, amdS+, ΔireA, pAMA-ireAThis study
MA169.4akusA::DR-amdS-DR, pyrG−This study
MA171.1kusA::DR-amdS-DR, pyrG+, ΔracAThis study
MA172.1kusA+, pyrG+, ΔracAThis study
MK15.AΔkus, pyrG+, ΔsrgAThis study
MK18.AkusA::DR-amdS-DR, pyrG+, ΔsrgAThis study

aStrains have been deposited at the Fungal Genetics Stock Center (www.fgsc.net)

To obtain pyrG− strains, 2 × 107 spores were inoculated on MM agar plates supplemented with 0.75 mg/ml 5′-fluoroorotic acid (FOA), 10 mM uridine and 10 mM proline as nitrogen source. Plates were incubated for 1–2 weeks at 30°C. FOA-resistant mutants were isolated, purified and tested for uridine auxotrophy on MM with and without uridine (mutants should not grow on medium lacking uridine). To obtain amdS− strains, 2 × 107 spores were inoculated on MM agar plates supplemented with 0.2% 5′-fluoroacetamide (FAA) and 10 mM urea as nitrogen source. After 1–2 weeks incubation at 30°C, FAA-resistant mutants were isolated, purified and tested for growth on acetamide medium (mutants should not grow on medium containing acetamide as sole nitrogen source).
All basic molecular techniques were performed according to standard procedures (Sambrook and Russel 2001 ). Transformation of A. niger, genomic DNA extraction, screening procedures, diagnostic PCR and Southern analysis were conducted as recently described in detail (Meyer et al. 2010 ).
Carvalho N.D., Arentshorst M., Jin Kwon M., Meyer V, & Ram A.F. (2010). Expanding the ku70 toolbox for filamentous fungi: establishment of complementation vectors and recipient strains for advanced gene analyses. Applied Microbiology and Biotechnology, 87(4), 1463-1473.
Publication 2010
5-fluoroorotic acid acetamide Agar casamino acids cesium chloride Diagnosis Edetic Acid fluoroacetamide Genes, Fungal Genome Glucose hygromycin A manganese chloride Methyldopa Nitrogen Nitrogen-10 Proline sodium molybdate(VI) Spores Strains Sulfate, Magnesium Urea Uridine Yeast, Dried
5
Assessment of Bipolar Prodromal Symptoms
All interviews for the RAP and AMDS studies were administered by a trained masters- or doctoral-level psychologist (RAP) and/or medical doctor (AMDS). Axis I diagnoses were assessed by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I/CV) (78 ), with added components from the Kiddie-Schedule for Affective Disorders and Schizophrenia (79 (link)) for childhood disorders not contained in the SCID (e.g., oppositional defiant disorder, conduct disorder, autism spectrum disorders), interviewing both the patient and the caregiver separately, integrating the results from the two separate interviews.
The BPSS-P (Correll CU, Auther AM, Cornblatt BA. The Bipolar Prodrome Symptom Interview and Scale–Prospective, unpublished manual.) is a semi-structured interview that was developed based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (38 ) criteria for BD and MDD, as well as established rating scales for mania, depression and other psychopathology. In addition, the BPSS-P development was informed by a review of existing literature regarding risk factors and early symptoms of BD (1 (link)), published scales and interviews for the assessment of the psychotic prodrome and character traits, input from experts in the areas of the schizophrenia prodrome and BD, and open questioning of youth with BD and their caregivers regarding emerging subthreshold symptoms prior to the onset of a first syndromal bipolar manic, mixed and major depressive episode. Finally, the identified items were used to develop the semi-structured Bipolar Prodrome Symptom Interview and Scale–Retrospective (BPSS-R) (25 (link)). The use of the BPSS-R in clinical samples of youth and young adults with established BD-I and BD-II further informed the final BPSS-P development.
The BPSS-P assesses the onset and severity of prodromal symptoms and is divided into three sections: Mania, Depression, and General Symptom Index (seeAppendix A). The format of the BPSS-P was modeled after the Scale of Prodromal Symptoms (SOPS) (74 (link)), such that each symptom is rated on the following ordinal scale: 0 = absent, 1 = questionably present, 2 = mild, 3 = moderate, 4 = moderately severe, 5 = severe, and 6 = extreme. Each symptom is assessed by specific probes and anchors for accurate ratings. The severity of the symptoms is assessed for the past month and the past year. Administration of the BPSS-P takes about one hour in HCs and 1.5–2.5 hours in psychiatric patients or their caregivers, depending on the extent and severity of past and current psychopathology.
To test inter-rater reliability, four raters/interviewers at the Masters (n = 1: SS), Ph.D. psychology (n = 2: AMA, MH), or medical doctor level (n = 1: TK) rated six reliability video tapes of a patient interview conducted by one of the four expert interviewers (one interview only contained the ten BPSS-P mania items plus mood lability, a general psychopathology item). These four raters had been trained on the BPSS-P, using three training videos and had at least two years (range: 2–6 years) of BPSS-P interview and rating experience.
The YMRS (80 (link)) was used to measure interviewer-rated manic symptoms. The Montgomery–Åsberg Rating Scale (MADRS) (81 (link)), which was administered in a subgroup of the AMDS sample (n = 61), was used to measure interviewer-rated depressive symptoms. The General Behavior Inventory-10-item Mania Form (GBI-M-10) (62 (link)) parent and respective patient self-report, which was added later to the assessment battery of the AMDS sample (n = 31), was used to measure self-reported mania-like symptoms. Temperament was measured with the Cyclothymic–Hypersensitive Temperament questionnaire (CHT) (82 (link)) of the Temperament Evaluation of Memphis, Pisa, Paris, and San Diego–Autoquestionnaire (TEMPS-A) (83 (link)).
Correll C.U., Olvet D.M., Auther A.M., Hauser M., Kishimoto T., Carrión R.E., Snyder S, & Cornblatt B.A. (2014). The Bipolar Prodrome Symptom Interview and Scale–Prospective (BPSS-P): description and validation in a psychiatric sample and healthy controls. Bipolar disorders, 16(5), 505-522.
Publication 2014
Autism Spectrum Disorders Character Conduct Disorder Depressive Symptoms Diagnosis Epistropheus Hypersensitivity Incipient Schizophrenia Interviewers Mania Mental Disorders Methyldopa Mood Mood Disorders Oppositional Defiant Disorder Parent Patients Physicians Prodromal Symptoms Psychologist Schizophrenia SCID Mice Syndrome Temperament Young Adult Youth

Most recents protocols related to «Methyldopa»

1
Acute Aortic Dissection Type A: Surgical Strategies
All patients undergoing emergency surgery for AADA between 2010 and 2020 in our department (n = 370) were retrospectively reviewed in a single center non-randomized retrospective observational cohort study design. Patient with subacute or chronic aortic dissection were excluded from the database. Detailed inclusion and exclusion criteria applied for patient selection are listed in Table 1. As a standard procedure for surgical treatment of AADA patients, all patients underwent replacement of the ascending aorta with distal anastomosis performed in circulatory arrest allowing an endoluminal inspection of the aortic arch to exclude entry sites at this region. Further extension of surgery toward the aortic root or the aortic arch was performed wherever relevant valvular pathology or extensive dissection, or tear was present at the level of the aortic root, or when an intimal tear was observed at the level of the aortic arch, respectively. A total of n = 120 patients with combined aortic root surgery and replacement of the proximal aortic arch without further treatment of the arch beyond the innominate artery and the supra-aortic vessels were identified and included. Surgery of the aortic root was defined as valve-sparing aortic root repair by the David procedure or root replacement by the Bentall procedure. Isolated use of surgical glue to realign the layers of the aortic wall was not considered as root surgery and not included. AADA patients who received concomitant AMDS implantation (n = 9, operated between August 2019 and December 2020) were compared to the remaining AADA patients without AMDS implantation (Control, n = 111, operated between January 2010 and October 2020). The excluded patients (n = 250) underwent a variety of different types of aortic surgery, including patients with isolated hemi-arch replacement without concomitant root surgery as well as total arch replacement. In patients with an intimal tear in the aortic arch, frozen elephant trunk procedure with a hybrid prosthesis was regularly performed.

Inclusion and exclusion criteria

Inclusion criteria
Acute aortic dissection type A
Emergency surgery
Age > 18 years
Exclusion criteria
 Intraoperative dissection
 Subacute or chronic aortic dissection
 No aortic valve surgery
 Surgery of the supra-aortic vessels
 Anastomosis beyond aortic arch zone 0
 Isolated repair of the aortic wall by surgical glue

Inclusion and exclusion criteria for patients participating in the study

Immohr M.B., Mehdiani A., Bauer S.J., Ise H., Sugimura Y., Lichtenberg A, & Akhyari P. (2023). Combining aortic arch dissection stent implantation and root surgery for aortic dissection type A. Journal of Cardiothoracic Surgery, 18, 72.
Full text: Click here
Publication 2023
Aorta Aortic Root Arch of the Aorta Ascending Aorta Blood Vessel Cardiac Arrest Cardiovascular System Dissecting Aneurysms Dissection Elephants Emergencies Freezing Hybrids Laceration Limb Prosthesis Methyldopa Operative Surgical Procedures Ovum Implantation Patient Isolation Patients Plant Roots Surgical Anastomoses Trunks, Brachiocephalic Tunica Intima Valves, Aortic Vascular Surgical Procedures
2
Betamethasone for Preterm Delivery Risk
Women with singleton pregnancies who were admitted to the Obstetric High Care Unit at Máxima MC with a risk for preterm delivery were recruited for this study. The aim was to include at least 50 patients. Those who received betamethasone (Celestone Chrondose®, Schering AG, Berlin, Germany; 2 doses of 12 mg intramuscularly, 24 h apart) as part of their standard clinical care were eligible to participate in the study. Co-administration of medications was allowed since this was part of the standard treatment protocol. Nifedipine was administered as a tocolytic to attenuate contractions as needed in cases of threatened preterm labor, at times in conjunction with indomethacin when contractions persisted while betamethasone treatment had not yet been completed. Antibiotics (erythromycin 250 mg, 4 times daily for 10 days) were administered to patients with preterm rupture of membranes to prevent infection. Furthermore, women with preeclampsia typically received antihypertensive drugs (specifically, methyldopa or labetalol). Patients under 18 years of age were not eligible for participation. Metadata collected from participants were indications for betamethasone administration, medications administered during the study period, parity, body mass index (BMI), gestational age at inclusion, and general and obstetric medical history [19 (link)].
Bester M., Joshi R., van Dooren J.H., Mischi M., Vullings R, & van Laar J.O. (2023). Changes in Maternal Heart Rate and Autonomic Regulation following the Antenatal Administration of Corticosteroids: A Secondary Analysis. Journal of Clinical Medicine, 12(2), 588.
Full text: Click here
Publication 2023
Antibiotics Antihypertensive Agents Betamethasone Celestone Erythromycin Fetal Membranes, Premature Rupture Gestational Age Index, Body Mass Indomethacin Infection Labetalol Methyldopa Nifedipine Patients Pharmaceutical Preparations Pre-Eclampsia Pregnancy Premature Birth Premature Obstetric Labor Tocolytic Agents Treatment Protocols Woman
3
Analytical Methods for Drug Quantification
All APIs (Table 1), SyrSpend® SF NEO and SyrSpend® SF PH4 were supplied by Fagron (São Paulo, Brazil). HPLC-grade reagents were procured from Vetec (Rio de Janeiro, Brazil). Ultrapure water, with an 18.2 MΩ cm resistivity at 25 °C and less than 10 ppb total organic carbon, was used throughout the experiments and produced using an AquaMax-Ultra 370 Series system (Young Lin, Anyang, Republic of Korea). The reference standards were acquired directly from the United States Pharmacopeia (USP, Rockville, MD, USA). Immediately before use, all mobile phases were filtered through a 0.45 mm filter membrane (RC-45/15 MS; Chromafil, Düren, Germany) and degassed for 30 min in an ultrasonic water bath (model 1600A; Unique, Indaiatuba, Brazil). All analytical balances and volumetric glassware were calibrated. For indomethacin, UHPLC analyses were performed in a qualified and calibrated Thermo Scientific (Waltham, MA, USA) equipment model Vanquis with software controller Chromeleon 7, version 7.3. HPLC analyses were performed in qualified and calibrated Young Lin equipment with a software controller Clarity version 8.1 (for levodopa/carbidopa, levothyroxine sodium and lomustine) or an Agilent (Santa Clara, CA, USA) equipment model 1260 Infinity with software controller OpenLab CDS version 2.7 (for clozapine, methyldopa and procarbazine).
Mansourian M., Dijkers E., Silva C.C, & Polonini H.C. (2023). Compatibility of Commonly Used Active Pharmaceutical Ingredients in a Ready-to-Use Oral Suspending Vehicle. Pharmaceutics, 15(10), 2388.
Full text: Click here
Publication 2023
Apis Bath carbidopa - levodopa Carbon-10 Clozapine High-Performance Liquid Chromatographies Indomethacin Levothyroxine Sodium Lomustine Methyldopa Procarbazine SyrSpend SF Tissue, Membrane Ultrasonics
4
Preeclampsia Case-Control Study in Iraq
This case-control study was conducted at the Women’s Obstetrics and Gynecology Hospital in Karbala Governorate, Iraq, from April to May 2023. Sixty patients with PE have participated in this study. The criteria of the American College of Obstetricians and Gynecologists were used for the diagnosis of definite PE [24 ]. Pregnant women were considered PE if they had a systolic blood pressure of 140 mm Hg or diastolic blood pressure of 90 mm Hg after 20 weeks of gestation and proteinuria (They should have normal blood pressure before). In the present study, the patients followed these criteria, and all patients had positive proteinuria in the dipstick test. They were fasted overnight and treated with methyldopa (Aldomet®). The gestational age was calculated from the last regular menstrual period, and the fundal height and ultrasound results were used for those women who could not remember their last menstrual period. Gravidity was recorded as the total number of pregnancies, including abortion, ectopic pregnancy, and any other pregnancies documented on the chart. Parity is defined as the number of deliveries after 28 weeks of gestation, including intrauterine fetal demise (IUFD) and stillbirth. The study was approved by the Institutional Review Board (IRB) of the Training and Human Development Center, Kerbala Health Department (Document number 585/2023), Kerbala, Iraq, which complies with the International Guideline for Human Research standards mandated by the Declaration of Helsinki.
Jasim Z.A., Al-Hakeim H.K., Zolghadri S, & Stanek A. (2023). Maternal Tryptophan Catabolites and Insulin Resistance Parameters in Preeclampsia. Biomolecules, 13(10), 1447.
Full text: Click here
Publication 2023
Aldomet Blood Pressure Diagnosis Ectopic Pregnancy Ethics Committees, Research Gestational Age Gynecologist Homo sapiens Human Development Induced Abortions Menstruation Methyldopa Obstetrician Patients Pregnancy Pregnant Women Pressure, Diastolic Systolic Pressure Ultrasonography Woman
5
Training Healthcare Workers on AMDS Implementation
Before the operationalisation of the AMDS, a pharmacist and nurse provider from each of the four sites, the national supply chain and ART coordinators were trained on how to operate and customise the AMDS. The training combined in-country and south-to-south experiential learning visits to health facilities and Call Centers in South Africa. During the experiential learning on the system, the visiting team was oriented to the set-up, client enrolment and process of resolving system malfunctions due to internet and electricity supply fluctuations. In addition, the South-to-South learning visit achieved other objectives, such as understanding how the AMDS functions and adaptations required for the Eswatini context, understanding possible challenges in the set-up and utilisation of the AMDS at the visited sites and how these were addressed, appreciating the roles and responsibilities of healthcare workers in the use of AMDS in designated facilities; understanding the standard operating procedures and how these can be adapted for each health facility; and learning about demand creation and recruitment strategies (marketing tools and health promotion) for AMDS for adaptation. On return, the team presented a report and key learnings to the MOH and stakeholders.
Williams V., Haumba S., Ngwenya-Ngcamphalala F., Mafukidze A., Musarapasi N., Byarugaba H., Chiripashi S., Dlamini M., Maseko T., Dlamini N.A., Nyapokoto C., Kibwana S., Bongomin P., Mazibuko S., Bhembe F., Ojoo S., Okello V, & Bazira D. (2023). Implementation of the Automated Medication Dispensing System–Early Lessons From Eswatini. International Journal of Public Health, 68, 1606185.
Full text: Click here
Publication 2023
Acclimatization Electricity Health Personnel Health Promotion Methyldopa Nurses

Top products related to «Methyldopa»

1
Methyldopa by Merck Group
Sourced in Poland
Methyldopa is a lab equipment product that serves as a precursor for the synthesis of various pharmaceutical compounds. It is a chemical compound with the molecular formula C10H13NO3. The core function of Methyldopa is to provide a starting material for further chemical transformations and reactions.
2
Zetasizer nano z by Malvern Panalytical
Sourced in United Kingdom, Germany, United States, France, Japan, China, Netherlands, Morocco, Spain, Cameroon
The Zetasizer Nano ZS is a dynamic light scattering (DLS) instrument designed to measure the size and zeta potential of particles and molecules in a sample. The instrument uses laser light to measure the Brownian motion of the particles, which is then used to calculate their size and zeta potential.
3
Amplex red by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Japan
Amplex Red is a fluorogenic probe used for the detection and quantitation of hydrogen peroxide (H2O2) and other peroxides. It is a colorless, non-fluorescent compound that becomes highly fluorescent upon oxidation by H2O2 in the presence of horseradish peroxidase (HRP). The resulting fluorescent product can be measured using a fluorescence microplate reader or fluorometer.
4
T4 dna ligase by Roche
Sourced in Germany, United States, Switzerland
T4 DNA ligase is an enzyme that catalyzes the formation of phosphodiester bonds between adjacent 3'-hydroxyl and 5'-phosphate termini in double-stranded DNA. It is derived from the T4 bacteriophage and is commonly used in molecular biology and genetic engineering applications for the ligation of DNA fragments.
5
Synergy 2 96 well plate reader by Agilent Technologies
The Synergy 2 96-well plate reader is a multi-mode microplate reader designed for a variety of detection technologies. It features a xenon flash lamp and dual optics design to enable absorbance, fluorescence, and luminescence measurements.
6
Puc118 by Takara Bio
Sourced in Japan, China
PUC118 is a plasmid vector designed for cloning and propagation of DNA sequences in Escherichia coli. It provides ampicillin resistance as a selectable marker and contains a multiple cloning site for insertion of DNA fragments.
7
Milli q purification system by Merck Group
Sourced in United States, Germany, France, Italy, Australia, China, Spain, United Kingdom, Brazil, India, Belgium
The Milli-Q purification system is a water purification solution designed to produce high-quality ultrapure water. It utilizes a multi-stage filtration process to remove a wide range of contaminants, including organic compounds, inorganic ions, and microorganisms, resulting in water with exceptionally low levels of impurities.
8
Baicalein by Merck Group
Sourced in United States, Germany, Poland, China, Canada
Baicalein is a natural compound derived from the root of the Scutellaria baicalensis plant. It is a yellow crystalline powder that is commonly used as a laboratory reagent for research purposes. Baicalein exhibits various biological properties that make it a valuable tool for scientific investigations, but a detailed description of its core function or intended use is not available in an unbiased and factual manner.
9
Potassium chloride (kcl) by Merck Group
Sourced in United States, Germany, United Kingdom, Italy, India, France, Spain, China, Belgium, Sao Tome and Principe, Canada, Denmark, Poland, Australia, Ireland, Israel, Singapore, Macao, Switzerland, Brazil, Mexico, Hungary, Netherlands, Egypt, Japan, Sweden, Indonesia, Czechia, Chile
Potassium chloride (KCl) is an inorganic compound that is commonly used as a laboratory reagent. It is a colorless, crystalline solid with a high melting point. KCl is a popular electrolyte and is used in various laboratory applications.
10
Hybond n membrane by Cytiva
Sourced in United Kingdom, United States, Sweden, Germany, China, Canada
Hybond-N+ membrane is a nylon-based membrane used for DNA and RNA transfer and immobilization in molecular biology applications. It provides a stable and efficient platform for blotting and hybridization experiments.

More about "Methyldopa"

Methyldopa, also known as alpha-Methyldopa, is a medication primarily used to treat high blood pressure (hypertension).
It works by reducing the activity of the sympathetic nervous system, which helps lower blood pressure.
Methyldopa is often prescribed for pregnant women with hypertension, as it is considered relatively safe for the developing fetus.
Researchers can utilize the AI-driven platform provided by PubCompare.ai to easily locate relevant research protocols on Methyldopa from literature, preprints, and patents.
This platform allows for smart comparisons, helping researchers identify the most reproducible and accurate methods, which can enhance Methyldopa research and acheive better results.
In addition to Methyldopa, researchers may also be interested in exploring other related topics and technologies, such as the Zetasizer Nano ZS (a dynamic light scattering instrument used for particle size and zeta potential analysis), Amplex Red (a fluorogenic probe used for the detection of hydrogen peroxide), T4 DNA ligase (an enzyme used in molecular biology for DNA ligation), Synergy 2 96-well plate reader (a microplate reader used for various assays), PUC118 (a commonly used cloning vector), Milli-Q purification system (a water purification system), Baicalein (a natural compound with potential therapeutic applications), KCl (potassium chloride, a common laboratory reagent), and Hybond-N+ membrane (a nylon membrane used for nucleic acid blotting).